

Abstrat

Objectives: To describe the epidemiological and histopathological aspects of kidney cancer in Cameroon. **Materials and Methods:** It was a descriptive retrospective study on malignant tumors of the kidney revealed in the anatomical pathology laboratories of five regions (Center, Littoral, West, South-west and North-west), over a period of 12 years (2004-2015). The studied parameters were: frequency, age, sex, histological type **Results:** A total of 110 cases of kidney cancer were collected, representing 8.55% of malignant urogenital tumors. The mean age of patients was 28.72±24.79 years (extremes: 4 months - 76 years). Females are relatively more affected than males (56 cases, 50.91%), with female-to-male ratio of 1.04:1. A total of 58 (52.73%) cases of renal cell carcinomas (RCC), 46 (41.82%) cases of nephroblastomas (NB) and 3 (2.73%) of Soft tissue tumors were identified. **Conclusion:** Kidney cancer is the third urogenital cancer in Cameroon characterized by the relative predominance of female and renal cell carcinoma as the predominant histological type.

Key words: Cancer, kidney, epidemiology, histopathology, Cameroon.

Introduction

Kidney cancer is currently the ninth common cancer in men and the 14th common in women worldwide. The highest rates of kidney cancer incidence (338,000 new cases, 2.4% of the world total) are estimated in Northern America, Australia, New Zealand and Europe. Incidence rates are lowest in Africa and in the Pacific Islands [1, 2]. Kidney cancer incidence and death rates are highest among AI/ANs, which may be due to high rates of obesity, smoking and hypertension [3]. Several histological types are known today including renal cell cancer (RCC), lymphoma, sarcoma and others [4]. Kidney cancer, predominantly renal cell carcinoma (RCC), is the most lethal genitourinary malignancy. The principal treatment kidney cancer are as follows: Surgery, Radiation therapy, Immunotherapy, Molecular-targeted therapy [5]. The 5-year age-standardised relative survival for patients with kidney tumors diagnosed in Europe during 2000–2007 was 60% [6]. In the USA, the 5-year relative survival rates is 72.6% for white and 68.0% for black patients [7]. In Cameroon, some characteristics studies of renal cancer were made, including Sow et al. This pathology represented 15.12% of all urogenital cancers [8]. Another made by Engbang et al in the littoral region, found a percentage, twice lower (7.91%) [9]. These data shows us the necessity of national data and prompted us to conduct this study to give the epidemiological histological close more boisterous.

2. Material and methods

It was retrospective and descriptive study of patients with kidney cancer confirmed histologically, diagnosed between January 2004 and December 2015. Data were obtained from histopathology, urology and oncology records of different health centers in five regions of Cameroon. Ethics Committee of all the concerned institutions approved the study protocol. The samples examined were mainly composed of biopsies and surgical specimens fixed in 10% formalin and processed according to the usual techniques of paraffin embedding,


43 microtome cutting and staining with hematoxylin-eosin. Only patients for whom the
44 **diagnosis** was confirmed by the histology were included in the study. The information
45 obtained included frequency, age, sex and histological type of the tumor. Data entry was done
46 using computer based statistical Package for Social Sciences (SPSS) version 20. The
47 descriptive statistics elements were used to calculate the frequencies and proportions.

48 3. Results

49 3.1. Epidemiological Aspects

50 3.1.1. Frequency of urogenital cancers in Cameroon

51 We collected 1286 cases of malignant urogenital tumors, from 2004 to 2015. Kidney
52 cancer (110 cases, **8.55%**) was in the second position after the prostate, followed by the
53 bladder (**Figure 1**).



54

55 **Figure 1. Distribution of urogenital cancers by seat.**

56 In table 1, prostate cancer was in the first rang (1047 cases, 87.10%), followed by bladder
57 cancer (60 cases, 4.99%) in males. In females, the kidney was the most affected urogenital
58 organ (56 cases, 66.67%), followed by the bladder (21 cases, 25.00%).

59

60

61

62

63

64

65

66


67 **Table 1. Distribution of urogenital cancers by seat and sex**

Organ	Males		Females		Total	
	Eff	%	Eff	%	Eff	%
Prostate	1047	87.10	-	-	1047	81.42
Kidney	54	4.49	56	66.67	110	8.55
Bladder	60	4.99	21	25.00	81	6.30
Testicle	30	2.50	-	-	30	2.33
Penis	10	0.83	-	-	10	0.78
Urethra	-	-	4	4.76	4	0.31
Ureter	1	0.08	3	3.57	4	0.31
	1202	100.00	84	100.00	1286	100,00

68 *Eff - Effective, % - Percentage*

69 Kidney cancer represented 94.02% (110/117) of all kidneys tumors.

70

71 **3.1.2. Sex**72 Females are relatively more affected than males (56 cases, 50.91%), female-to-male
73 ratio was 1.04:174 **3.1.3. Age**75 Age ranged from 4 months to 76 years with average of 28.72 ± 24.79 years (33.90
76 years in men, 23.86 years in women). As shown in figure 2, patients from 0 to 9 years, are
77 more affected, with a percentage of 39.47% (45 cases).

78

79 **Figure 2. Distribution according to age groups and sex.**

80

81 **3.2. Histopathological Aspects**

A total of 58 (52.73%) cases of Renal cell Carcinomas (RCC), 46 (41.82%) cases of nephroblastomas (NB) and 3 (2.73%) of soft tissue tumors have been identified (Table 2).

Table 2. Relationship between histological types and age

AGE		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	TOTAL	%	%
A	ccRCC	-	1	3	10	9	4	2	1	30	27.27	
	pRCC	-	1	1	1	1	3	3	-	10	9.09	
	chRCC	-	-	-	2	-	-	-	1	3	2.73	
	cdRCC	1	-	-	-	1	1	-	-	3	2.73	52.73
	mRCC	-	-	-	-	-	1	-	-	1	0.91	
	RCAN	1	-	-	-	-	-	-	-	1	0.91	
	ucRCC	-	-	2	1	1	2	3	1	10	9.09	
B	NB	43	1	1	-	-	-	-	1	46	41.82	41.82
C	CCSK	-	-	-	-	-	1	-	-	1	0.91	
	RAS	-	-	-	-	-	1	-	-	1	0.91	2.73
	RRMS	-	-	-	-	-	-	-	1	1	0.91	
D	RC	-	-	-	-	-	1	-	-	1	0.91	0.91
E	Lymphoma	-	-	-	-	-	-	2	-	2	1.82	1.82
Total		45	3	7	14	12	14	10	5	110	100.00	100.00

A-Renal Cell Carcinoma, B-Nephroblastic Tumors, C-Soft Tissue Tumors, D-Neural/Neuroendocrine Tumors, E-Hematopoietic and Lymphoid Tumors. RCC-Renal Cell Carcinoma, ccRCC-Clear Cell, pRCC-papillary, cdRCC-Collecting ducts, mRCC-Medullary, RCAN-Renal Carcinoma Associated with Neuroblastoma, ucRCC-Unclassified, NB-Nephroblastoma, CCSK-Clear Cell Sarcoma of the Kidney, RAS-Renal Angiosarcoma, RRMS-Renal Rhabdomyosarcoma, RC-Renal Carcinoid

In table 3, people with RCC were more likely to be male (31 cases, 53.45%), in that group a substantial higher proportion of ccRCC was female (20 cases, 66.67%). People with NB were significantly more likely to be female (28 cases, 61.87%).

Table 3. Relationship between histological types and sex

Histological Type	Male		Female		Total	
	EFF	%	EFF	%	EFF	%
ccRCC	10	18.52	20	35.71	30	27.27
pRCC	8	14.81	2	3.57	10	9.09
chRCC	1	1.85	2	3.57	3	2.73
cdRCC	3	5.56	-	-	3	2.73
mRCC	1	1.85	-	-	1	0.91
RCAN	-	-	1	1.79	1	0.91
ucRCC	8	14.81	2	3.57	10	9.09
NB	18	33.33	28	50.00	46	41.82
CCSK	1	1.85	-	-	1	0.91
RAS	-	-	1	1.79	1	0.91
RRMS	1	1.85	-	-	1	0.91
RC	1	1.85	-	-	1	0.91
Lymphoma	2	3.70	-	-	2	1.82

Discussion

Kidney cancers (8.55%) were in the second position after prostate. According to many authors, kidney cancers were in the third position among urogenital malignant tumors. For Darre et al. in Togo, although his percentage was lower than ours (8.11 %), this pathology come after bladder cancer [10]. Ouattara in Benin and Sow in Cameroon found respectively 8.5 and 15.12% [11,7]. These African datas (Black) can be associated with that of the Unites States one, where they observed an increase in incidence of renal cell cancer among blacks than whites. The RCC subtype distribution was different in black people from that of white, with a substantially higher proportion of patients with papillary RCC among blacks than white people [12, 13]. Although so far the real reason is not yet found, some theories are trying to explain this phenomenon. The observed differences between blacks and whites in early stage of renal cell tumor distribution dating back to the 1970s is unlikely to be a result of long-term access to and utilization of imaging technologies by blacks [12]. Renal cell cancer may be a less aggressive tumor among blacks, as suggested by the favorable stage distribution and their higher survival, particularly for distant and unstaged cancer [14]. An estimated 2-4% of kidney cancers are caused by inherited factors [15]. Clear cell RCC is associated with cytogenetic loss of chromosome 3p, encompassing four of the most commonly mutated genes in this cancer: the closely linked Von Hippel–Lindau (VHL) tumor suppressor gene which has been identified to be inactivated about 92% of cases. 61% of renal cell carcinoma cases have Von Hippel Lindau mutations [16, 17]. The VHL gene produces a protein that targets hypoxia inducible factors (HIFs) for ubiquitin-mediated degradation. Loss of function leads to accumulation of HIFs and subsequent upregulation of vascular endothelial growth factor and other factors that promote angiogenesis and tumour growth [18]. And the more recently recognized high-frequency mutations in PBRM1 (polybromo 1), BAP1 [BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)], and SETD2 (SET domain containing 2) [19]. Either papillary nor chromophobe histology tumors have been associated with any of these genomic alterations.

Female-to-male ratio in our series was 1.04:1. Fall and al in Senegal revealed also the female domination (51.3%) [20]. In Togo, females subjects were affected in 56.36 % [10]. A study from Nigeria published report worldwide showing a clear female predominance (a male to female ratio of 1:2.1) [21]. This is in contrast with Ouattara et al, who found the predominance of male with a sex ratio (male to female) of 11/3 [11]. Honde also observed that 63% of males were infected (sex ratio 1.7) [22]. Cigarette smoking can play a great role in the evolution of RCC. An estimated 29% of kidney cancers in men, and 15% in women, in the United Kingdom are caused by smoking [23]. Hunt et al reported statistically significant relative risks of 1.5 and 1.2 for male and female smokers, respectively. In that study, there was firstly a strong dose-dependent increase in risk, up to 2- and 1.6-fold (21 or more cigarettes per day) among heavy men and women smokers, respectively; secondly a significant decline in risk in both sexes with years of cessation (10 to 15 years after quitting), with a 15 to 30% risk reduction [24]. Kidney cancer risk is 52-54% higher in current smokers compared to never-smokers; it is 58-103% higher in those who smoke more than 20 cigarettes per day, compared to never-smokers. It's also important to know that the risk among ex-smokers who quit more than 10 years ago is comparable to that of never-smokers

[25]. Cigarette smoking is not implicated only to renal cell carcinogenesis, but also may promote cancer progression that may translate into more advanced disease [26]. Several mechanisms have been suggested to explain how smoking induce renal damage, including the tubulotoxic effects, hemodynamic changes, endothelial cell dysfunction and oxidative stress [27, 28]. These toxic effects may increase cell turnover and induce DNA damage, which are potentially involved in carcinogenesis and cancer progression. We know also that tobacco smoking is associated with a myriad of genetic and epigenetic abnormalities such as gene mutations, deletions, and DNA methylation. For instance, polycyclic aromatic hydrocarbons present in tobacco smoke can induce mutations in the p53 gene, which can potentially lead to accelerated cancer progression [29]. Smoking has also been demonstrated to have an effect on the immune system, promoting inflammation and suppressing the immune function by reducing T-cell and natural killer cell activation [30]. Both pathways (inflammation and immune suppression) could facilitate neoplastic growth. Furthermore, nicotine contained in tobacco smoke has been associated with alteration of the vascular endothelial growth factor signaling pathway [31].

The median age of our patients was 28.72 ± 24.79 years (33.90 years in men, 23.86 years in women), with extremes ranging from 4 months to 76 years. The most affected group was patients from 0 to 9 years, with a percentage of 39.47% (45 cases). Darre in Togo revealed a mean age of 35.9 years with extremes from 11 to 83 [10]. Ouattara in Benin found 53.21 ± 15.55 years, Honde in Ivory Coast – 40.9 years (15-67 years) [11, 22]. The mean age at diagnosis was 54.7 years, 50 years and 56.9 years in men and 51.9 years, 41.5 years and 57.6 years United Arab Emirates (UAE), Algeria and Jordan respectively [32]. In Morocco the median age at diagnosis was 57 years in men and 53 years in women [32]. Some other factors such as obesity, diabetics and hypertension can be considered as risks factors. Wilms tumor risk is higher in children with a higher birth-weight [33]. Kidney cancer risk among men is 22% higher in those who are overweight (body mass index [BMI] 25-30) and 63% higher in those who are obese (BMI 30+)[34]. Kidney cancer risk among women is 38% higher in those who are overweight and 95% higher in those who are obese [34]. Obesity might be associated with increased risk of kidney cancer through several hormonal mechanisms. A potential mechanism by which obesity may increase kidney cancer risk involves increased levels of insulin-like growth factor (IGF) or lipid peroxidation. Increasing BMI is associated with elevated levels of fasting serum and free IGF-I among men and women, which contributes to the stimulation of renal cell proliferation and inhibition of apoptosis, which could have a profound impact on tumour growth [35, 36]. Obesity also affects the hormonal milieu by increasing levels of free endogenous oestrogen, which may in turn influence renal cell proliferation and growth by direct endocrine receptor-mediated effects, via regulation of receptor concentrations or through paracrine growth factors [37]. Obesity may also induce chronic low-grade inflammation resulting in an alteration of local and systemic levels of cytokines (e.g., interleukin-6, C-reactive protein) and adipokines (e.g., leptin, adiponectin), which may play a role in bladder carcinogenesis to bladder cancer mortality [38, 39]. People with high BMI have been reported to have higher glomerular filtration rate and renal plasma flow, which may increase the risk of kidney damage, and thereby render the kidney more susceptible to carcinogen [40]. Analyses had determined a loss of activity in the VHL tumor suppressor gene causes an increase in the expression of the very low-density lipoprotein receptor (VLDL-R) on RCC cells, resulting to an increase in cholesterol ester uptake from the systemic circulation, with subsequent growth of adipose

deposits inside the renal tubular epithelium [41]. Hyperplasia and hypertrophy induced by increased cholesterol uptake in kidney cells increases the metabolic rate in the individual capillary beds feeding this tissue, which subsequently leads to a relative tissue hypoxia. In response to this oxygen deficit, the tissues up-regulate production of hypoxia-inducible factor-1- α (HIF-1 α) [42]. HIF-1 α suppresses cellular apoptosis and up-regulates expression of vascular endothelial growth factor (VEGF) [42]. Suppression of cellular apoptotic mechanism permits abnormal cells to proliferate and VEGF promotes local blood vessel proliferation (neoangiogenesis), both of which are characteristic of RCC tumor growth.

Concerning diabetics and hypertension, we can say that diabetes was associated with the increased risk of bladder cancer [43]. Type 2 diabetes is associated with insulin resistance, compensatory hyper-insulinemia, and up-regulated level of IGF-1. IGF-1 could stimulate cell proliferation and inhibit apoptosis, which could have a profound impact on tumour growth [35, 36]. diabetes is also associated with an increased risk of urinary tract infection and urinary tract calculi, which have been related to various histologic types of bladder cancer, including transitional cell carcinoma, the predominant type [44, 45, 46]. The accumulation of oxidative DNA damage, which was increased through the hyperactivation of Akt/tuberin/mTOR pathway in kidney cancer patients with diabetes, may play an important role in initiating kidney tumorigenesis [47]. Kidney cancer risk is 62% higher in people with a history of hypertension; this may relate to hypertension treatment but evidence is unclear [48]. Several biologic mechanisms for the association between high blood pressure and renal cell cancer risk have been proposed, including hypertension-induced renal injury, metabolic or functional changes within the renal tubule induced by hypertension, increasing susceptibility to carcinogens. It has also been speculated that elevated levels of insulin-like growth factor-I (IGFI) or lipid peroxidation associated with hypertension, as well as up-regulation of hypoxia-inducible factors, could contribute to the development of renal cell cancer [12].

We found 58 (52.73%) cases of renal cell carcinomas (RCC), 46 (41.82%) cases of nephroblastomas (NB) and 3 (2.73%) of soft tissue tumors. Ghosn et al revealed a predominance of clear cell carcinoma: 79% in UAE and 68% in Morocco [32]. In Togo, Darre described 50.90 % of nephroblastoma, 23.63 % of ccRCC and 7.27 % of Lymphoma [10]. In Ivory Coast, RCC – 85.2% (78.3% of ccRCC) and 14.8% of NB [22]. Sow et al in Cameroon found 74.10% of NB [49]. In our studies, people with RCC were more likely to be male (31 cases, 53.45%), in that group a substantial higher proportion of ccRCC was female (20 cases, 66.67%). People with NB were significantly more likely to be female (28 cases, 61.87%). In the literature, the most frequent histological subtypes of RCC include clear cell renal cell carcinomas (ccRCC), papillary renal cell carcinomas (pRCC), and chromophobe renal cell carcinomas (crRCC). These three subtypes together represent more than 90% of all RCCs [49]. CcRCC is the most common variant, representing between 70% and 75% of all RCCs. Most clear cell carcinomas (95%) are sporadic, and the remaining 5% are associated with hereditary syndromes (von Hippel-Lindau disease, tuberous sclerosis) [50]. Lipworth in USA revealed that substantially higher proportion of patients with papillary RCC among black people than white; compared with clear-cell RCC, people with papillary RCC were significantly more likely to be black and less likely to be female. People with chromophobe RCC were significantly more likely to be female [13]. Primary angiosarcoma of the kidney is extremely rare; in the literature, The disease arises significantly more frequent in men than

women . Median age of patients was 59.9 ± 12.6 years, range mainly from 50 to 69 years old [51]. Renal RMS in adults is also extremely uncommon. Histologically, the primary renal RMS is a high-grade tumor that needs to be differentiated from other malignant lesions, such as sarcomatoid renal cell carcinoma, metastatic carcinoma or melanoma, and rhabdoid tumor [52].

Conclusion

Kidney cancer is the third urogenital cancer in Cameroon characterized by relative predominance of female and renal cell cancer as the predominant histological type. The fight against smoking, the prevention of diseases such as hypertension and diabetes are among the key elements that can work for the decrease in the prevalence of this pathology. It should be noted that the effective initiation of cancer registries is still essential to mastery of the epidemiological data, foundation for a better coordination of prevention of the anti-cancer fight.

References

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2014.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer*. 2015; 136: E359–E386
3. White MC, Espey DK, Swan J, Wiggins CL, Ehemann C, Kaur JS. Disparities in cancer mortality and incidence among American Indians and Alaska Natives in the United States. *Am J Public Health*. 2014; 104(suppl3):S377-S387.
4. Chow W-H, Shuch B, Linehan WM, Devesa SS. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. *Cancer*. 2013; 119(2): 388–394
5. North A S, Basappa C, Canil C, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. *Can Urol Assoc J*. 2015;9(5-6):164-70
6. Marcos-Grageraa R, Malloneb S, Kiemeneyc A L, et al. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EURO CARE-5. *European Journal of Cancer*. 2015; 51(15): 2217–2230
7. Moch H, Cubilla LA, Humphrey AP, Reuter E V, Ulbright MT. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. *European urology*. 2016 ; 70: 93 – 105
8. Sow M, Blaise Nkégom B, Essame Oyono JL, Nzokou A. Aspects épidémiologiques et histopathologiques des tumeurs urogénitales au Cameroun. *Prog Urol*. 2006;16:36-39
9. Engbang NJP, Sala B, Moby H, Fonkwa C, Essomba B, Essam Sime JD, Ateba G, Fewou A. Cancers urogénitaux dans la région du littoral-Cameroun : épidémiologie et histopathologie. *Revue de Médecine et de de pharmacie*. 2014 ; 4 (2) : 440-446

- 274 10. Darré T, Améghor K, Kpatcha M, Tengue K et al. Urologic cancers in Togo: histo-
275 epidemiological profile of 678 cases. *J. Afr. Cancer*.2014 ; 6:27-31
- 276 11. Ouattara A, Hodonou R, Avakoudjo J, Cisse D, Zango B et al. Épidémiologie des
277 cancers urologiques au Centre national hospitalier universitaire Hubert Koutoukou
278 Maga Cotonou, Bénin. Analyse d'une série hospitalière de 158 cas. *Prog Urol*. 2012 ;
279 22 :(5)261-265
- 280 12. Loren Lipworth , Robert E Tarone, Joseph K McLaughlin. Renal cell cancer among
281 African Americans: an epidemiologic review. Lipworth et al. *BMC Cancer*. 2011;
282 11:133 <http://www.biomedcentral.com/1471-2407/11/133>
- 283 13. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD et al.
284 Renal cell cancer histological subtype distribution differs by race and sex. *BJU Int*.
285 2016 Feb; 117(2):260-5.
- 286 14. Lipworth L, McLaughlin JK, Tarone RE, Blot WJ: Renal cancer paradox: Higher
287 incidence but not higher mortality among African Americans. *Eur J Cancer Prev*.
288 2011 Jul;20(4):331-3.
- 289 15. Bausch B, Jilg C, Gläsker S, et al. Renal cancer in von Hippel-Lindau disease and
290 related syndromes. *Nat Rev Nephrol*.2013; 9(9):529-38.
- 291 16. Nickerson, M. L., E. Jaeger, Y. Shi, J. A. Durocher, S. Mahurkar, D. Zaridze, et al.
292 Improved identification of von Hippel-Lindau gene alterations in clear cell renal
293 tumors. *Clin. Cancer Res*. 2008; 14:4726–4734.
- 294 17. vanHouwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of
295 von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The
296 Netherlands cohort study . *BMC Cancer*.2005; 2:5:57.
- 297 18. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for
298 disease-specific approaches to therapy. *Expert OpinBiolTher*. 2008;8:779–90.
- 299 19. Kapur, P., S. Pena-Llopis, A. Christie, L. Zhrebker, A.Pavia-Jimenez, W. K.
300 Rathmell, et al. BrugarolasEffects on survival of BAP1 and PBRM1 mutations
301 insporadic clear-cell renal-cell carcinoma: a retrospectiveanalysis with independent
302 validation. *Lancet Oncol*. 2013 ; 14:159–167.
- 303 20. Fall B, Diao B, Sow Y, Sarr A, Thiam A et al. Le cancer du rein de l'adulte au
304 Sénégal: aspects épidémiologiques et cliniques actuels et évolution du profil sur les
305 deux dernières décennies. *Prog Urol*. 2011; 21(8):521-526
- 306 21. Odubango MO, Oluwasola AO, Ikuerowo SO, et al. Histopathological pattern of renal
307 cell carcinoma in Ibadan. *Afr J Med Med Sci*.2010 ; 39:317-321
- 308 22. Honde M, Koffi K, Ette-Dieng E, Boka MB et al. Aspects épidémiologiques et
309 caractéristiques histologiques du cancer du rein de l'adulte a abidjan - Cote d'Ivoire.
310 *Médecine d'Afrique Noire*. 1998 ; 45 (7) : 448-450
- 311 23. Coglianò VJ, Baan R, Straif K, et al. Preventable exposures associated with human
312 cancers (link is external). *JNCI*. 2011; 103:1827-39

313 24. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P: Renal cell carcinoma
314 in relation to cigarette smoking: meta-analysis of 24 studies. *Int J Cancer*. 2005;
315 114:101-108.

316 25. Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to
317 cigarette smoking: meta-analysis of 24 studies (link is external). *Int J Cancer*. 2005;
318 114:101-8

319 26. Parker A, Lohse C, Cheville J, et al: Evaluation of the association of current cigarette
320 smoking and outcome for patients with clear cell renal cell carcinoma. *Int J*
321 *Urol*.2008; 15:304-308

322 27. MatveyTsvian, Daniel M. Moreira, Jorge R. Caso, Vladimir Mouraviev, and Thomas
323 J. Polascik. Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma. *J*
324 *ClinOncol*. 2011; 29(15):2027-2031

325 28. Orth S. Cigarette smoking: An important renal risk factor—Far beyond
326 carcinogenesis. *TobInducDis*. 2003; 1:137-155

327 29. Kudahetti S, Fisher G, Ambroisine L, et al. p53 immunochemistry is an independent
328 prognostic marker for outcome in conservatively treated prostate cancer. *BJU*
329 *Int*.2009; 104:20-24

330 30. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm*
331 *Res*.2008; 57:497-503

332 31. Mousa S, Mousa SA. Cellular and molecular mechanisms of nicotine's pro-
333 angiogenesis activity and its potential impact on cancer. *J Cell Biochem*.2006;
334 97:1370-1378

335 32. Ghosn M, Jaloudi M, Larbaoui B, Adib S, Dreosti L, Zekri J. Insights into the
336 epidemiology of renal cell carcinoma in North Africa and the Middle East. *Pan Arab*
337 *Journal of Oncology*. June 2015; 8 (2): 38-43

338 33. Chu A, Heck JE, Ribeiro KB, et al. Wilms' tumour: a systematic review of risk factors
339 and meta-analysis. *Paediatr Perinat Epidemiol*. 2010; 24:449-69.

340 34. Wang F, Xu Y. Body mass index and risk of renal cell cancer: A dose-response meta-
341 analysis of published cohort studies. *Int J Cancer*. 2014; 135:1673-1686.

342 35. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like
343 growth factors in human obesity. *Metabolism*. 1995; 44:37 – 44

344 36. Yu H, Rohan T. Role of the insulin-like growth factor family in
345 cancer development and progression. *J Natl Cancer Inst*.2000; 92:1472 – 148

346 37. Zumoff B. Hormonal abnormalities in obesity. *Acta Med Scand*. 1988;723:153–60

347 38. Sun J-W, Zhao L-G, Yang Y, Ma X, Wang Y-Y, Xiang Y-B. Obesity and Risk of
348 Bladder Cancer: A Dose-Response Meta-Analysis of 15 Cohort Studies.
349 *PLoS ONE*.2015; 10(3): e0119313

39. Hilmy M, Bartlett JMS, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. *Br J Cancer*. 2005; 92: 625–627
40. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. *Hypertension*. 1995;26:610–5.
41. Sundelin JP. Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. *PLoSOne*.2012; 7(11): e48694.
42. Zhang GM, Zhu Y, Ye D-W. Metabolic syndrome and renal cell carcinoma. *World J SurgOncol*.2014; 12: 236.
43. Chen L, Li H, Gu L, Ma X, Li X, Gao Y, et al. The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies. *Medicine (Baltimore)*. 2015 Jul;94(26):e1055
44. GeerlingsSE, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and Urinary Tract Infections in Diabetes: Impact of Pharmacologically-Induced Glucosuria. *Diabetes Research and Clinical Practice*. 2014;103, 373-381.
45. Chen HS, Su LT, Lin SZ, Sung FC, Ko MC, et al. Increased risk of urinary tract calculi among patients with diabetes mellitus—a population-based cohort study. *Urology*.2012;79: 86–92.
46. Jankovic S, Radosavljevic V. Risk factors for bladder cancer. *Tumori*.2007; 93:4–12.
47. Habib SL, Liang S. Hyperactivation of Akt/mTOR and deficiency in tuberlin increased the oxidative DNA damage in kidney cancer patients with diabetes. *Oncotarget*. 2014; 5:2542–2550.
48. Corrao G, Scotti L, Bagnardi V, Sega R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. *Curr Drug Saf*. 2007;2:125-33
49. Sow M, Mbakop A, Obama MT, Tedjoua E et al. Les tumeurs du rein en milieu africain. Incidence et aspects anatomo-cliniques. A propos de 123 cas observés à l'Hôpital Central et au C.H.U. de Yaoundé (Cameroun). *Pro Urol*. 1994; 4 : 214-218
50. Lopez-Beltran A, Carrasco JC, Cheng L, et al. 2009 update on the classification of renal epithelial tumors in adults. *Int J Urol*. 2009; 16:432–43
51. Zhang H-M , Yan Y, Luo M, Xu Y-F, Peng B, Zheng J-H. Primary angiosarcoma of the kidney: case analysis and literature review. *Int J ClinExpPathol*. 2014;7(7):3555-3562
52. Dalfior D, Eccher A, Gobbo S, Brunelli M, Marignoni G, Menestrina F, Dalla PP, Dvornik G. Primary pleomorphic rhabdomyosarcoma of the kidney in an adult. *Ann DiagnPathol*.2008; 12(4): 301-3.